What is Denali Therapeutics Debt-to-Equity?
Denali Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $7.3 Mil. Denali Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $45.0 Mil. Denali Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,031.0 Mil.
Denali Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.05.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Denali Therapeutics's Debt-to-Equity or its related term are showing as below:
DNLI'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.05 Med: 0.06 Max: 0.18
Current: 0.05
During the past 9 years, the highest Debt-to-Equity Ratio of Denali Therapeutics was 0.18. The lowest was 0.05. And the median was 0.06.
Denali Therapeutics Debt-to-Equity Historical Data
The historical data trend for Denali Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics Debt-to-Equity Chart
|
Denali Therapeutics Annual Data
|
|
Trend |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
|
0.18 |
0.06 |
0.07 |
0.06 |
0.05 |
|
Denali Therapeutics Quarterly Data
|
|
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.06 |
0.06 |
0.05 |
0.05 |
0.05 |
Competitive Comparison of Denali Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Denali Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Denali Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Denali Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Denali Therapeutics's Debt-to-Equity falls into.
Denali Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Denali Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as
Denali Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Denali Therapeutics (Denali Therapeutics) Business Description
Traded in Other Exchanges
Address
161 Oyster Point Boulevard, South San Francisco, CA, USA, 94080
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.
Executives
| Vicki L Sato |
director |
940 WINTER STREET, PERKINELMER, INC. LEGAL DEPARTMENT, WALTHAM MA 02451 |
| Carole Ho |
officer: Chief Medical Officer |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Ryan J. Watts |
director, officer: President and CEO |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Steve E. Krognes |
officer: CFO and Treasurer |
863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010 |
| Alexander O. Schuth |
officer: COO and Secretary |
C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
| Marc Tessier-lavigne |
director |
1 DNA WAY, SOUTH SAN FRANCISCO CA 94080 |
| Erik Harris |
director |
60 LEVERONI COURT, NOVATO CA 94949 |
| Douglas K Bratton |
10 percent owner |
201 MAIN STREET, SUITE 1900, FORT WORTH TX 76102 |
| Nancy Thornberry |
director |
SCHRODINGER, INC., 120 WEST 45TH STREET, 17TH FLOOR, NEW YORK NY 10036 |
| David P Schenkein |
director |
C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139 |
| Biogen Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Biogen Ma Inc. |
10 percent owner |
225 BINNEY STREET, CAMBRIDGE MA 02142 |
| Arch Venture Partners Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Partners Viii, Llc |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
| Arch Venture Fund Viii, L.p. |
10 percent owner |
8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
Denali Therapeutics (Denali Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DNLI has been successfully added to your